Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$135.55
+0.1%
$128.89
$119.59
$146.85
$15.05B0.911.05 million shs89,149 shs
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
$6.70
-3.2%
$7.34
$6.52
$8.65
$2.57B1.1613,384 shs13,050 shs
Guardant Health, Inc. stock logo
GH
Guardant Health
$17.33
+1.0%
$18.94
$15.81
$41.06
$2.11B0.871.87 million shs174,810 shs
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
$199.06
+0.4%
$212.06
$174.20
$234.09
$16.75B1.01748,786 shs155,459 shs
Invitae Co. stock logo
NVTA
Invitae
$0.01
+800.0%
$0.01
$0.02
$0.02
$2.40M1.5923.72 million shs1.43 million shs
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
-1.51%+7.58%+5.17%+3.85%-7.74%
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
-3.18%-1.11%-11.43%-10.79%-18.98%
Guardant Health, Inc. stock logo
GH
Guardant Health
-5.19%+2.94%-3.00%-25.71%-18.05%
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
-4.61%-0.55%-7.10%-11.77%-10.55%
Invitae Co. stock logo
NVTA
Invitae
0.00%-70.59%-92.86%-99.76%-99.92%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
4.8782 of 5 stars
2.13.04.24.73.72.52.5
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
2.9769 of 5 stars
0.03.02.50.02.21.72.5
Guardant Health, Inc. stock logo
GH
Guardant Health
4.5343 of 5 stars
4.41.00.04.62.43.30.6
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
4.9266 of 5 stars
3.43.02.54.23.12.52.5
Invitae Co. stock logo
NVTA
Invitae
2.3099 of 5 stars
2.50.00.04.62.31.71.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
2.25
Hold$146.177.83% Upside
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
1.00
SellN/AN/A
Guardant Health, Inc. stock logo
GH
Guardant Health
2.85
Moderate Buy$39.27126.62% Upside
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
2.79
Moderate Buy$244.2122.68% Upside
Invitae Co. stock logo
NVTA
Invitae
1.00
Strong Sell$1.0011,011.11% Upside

Current Analyst Ratings

Latest DGX, LH, GH, NVTA, and EKTAY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/26/2024
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$234.00 ➝ $213.00
4/26/2024
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$255.00 ➝ $244.00
4/25/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$138.00 ➝ $144.00
4/24/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$135.00 ➝ $145.00
4/24/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$139.00 ➝ $146.00
4/24/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$145.00 ➝ $150.00
4/24/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$150.00 ➝ $155.00
4/24/2024
Guardant Health, Inc. stock logo
GH
Guardant Health
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
4/15/2024
Guardant Health, Inc. stock logo
GH
Guardant Health
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $28.00
4/5/2024
Guardant Health, Inc. stock logo
GH
Guardant Health
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral
3/25/2024
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy$250.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$9.25B1.63$12.56 per share10.79$58.25 per share2.33
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
$1.61B1.59$0.54 per share12.33$2.43 per share2.76
Guardant Health, Inc. stock logo
GH
Guardant Health
$563.95M3.74N/AN/A$1.34 per share12.93
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
$12.16B1.38$19.46 per share10.23$92.76 per share2.15
Invitae Co. stock logo
NVTA
Invitae
$481.58M0.00N/AN/A$0.42 per share0.02

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$854M$7.4318.2414.392.979.11%15.52%7.23%7/24/2024 (Estimated)
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
$90.25M$0.3618.6114.26N/A7.88%15.16%5.01%N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
-$479.45M-$4.28N/AN/AN/A-85.02%-301.94%-27.65%5/9/2024 (Confirmed)
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
$418M$4.6742.6312.431.563.24%13.99%6.82%7/25/2024 (Estimated)
Invitae Co. stock logo
NVTA
Invitae
-$3.11B-$5.38N/AN/AN/A-299.14%-6,100.71%-19.68%N/A

Latest DGX, LH, GH, NVTA, and EKTAY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.7220N/A+$0.7220N/AN/AN/A  
4/25/2024Q1 2024
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
$3.46$3.68+$0.22$4.67$3.12 billion$3.18 billion    
4/23/2024Q1 2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$1.86$2.04+$0.18$2.36$2.29 billion$2.37 billion      
2/29/2024Q3 2024
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
N/A$0.08+$0.08$0.08N/A$426.51 million
2/22/2024Q4 2023
Guardant Health, Inc. stock logo
GH
Guardant Health
-$0.93-$1.58-$0.65-$1.58$151.71 million$155.05 million
2/15/2024Q4 2023
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
$3.29$3.30+$0.01$8.55$3.02 billion$3.03 billion    
2/1/2024Q4 23
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$2.11$2.15+$0.04$2.60$2.25 billion$2.29 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
$2.842.10%+8.08%38.22%13 Years
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
$0.162.39%N/A44.44%N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
N/AN/AN/AN/AN/A
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
$2.881.45%N/A61.67%N/A
Invitae Co. stock logo
NVTA
Invitae
N/AN/AN/AN/AN/A

Latest DGX, LH, GH, NVTA, and EKTAY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/11/2024
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
Quarterly$0.721.39%5/24/20245/28/20246/12/2024
2/1/2024
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
quarterly$0.752.34%4/5/20244/8/20244/22/2024
1/30/2024
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
$0.11462/26/20242/27/20243/18/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.59
0.97
1.20
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
0.57
1.12
0.83
Guardant Health, Inc. stock logo
GH
Guardant Health
7.18
6.54
6.24
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
0.52
1.17
1.02
Invitae Co. stock logo
NVTA
Invitae
N/A
2.39
2.25

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
88.06%
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
N/A
Guardant Health, Inc. stock logo
GH
Guardant Health
92.60%
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
95.94%
Invitae Co. stock logo
NVTA
Invitae
61.28%

Insider Ownership

CompanyInsider Ownership
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
0.79%
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
41.28%
Guardant Health, Inc. stock logo
GH
Guardant Health
6.20%
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
0.85%
Invitae Co. stock logo
NVTA
Invitae
0.74%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Quest Diagnostics Incorporated stock logo
DGX
Quest Diagnostics
48,000111.06 million110.18 millionOptionable
Elekta AB (publ) stock logo
EKTAY
Elekta AB (publ)
4,540383.57 million225.23 millionNot Optionable
Guardant Health, Inc. stock logo
GH
Guardant Health
1,779121.71 million114.17 millionNot Optionable
Laboratory Co. of America Holdings stock logo
LH
Laboratory Co. of America
67,00084.13 million83.41 millionOptionable
Invitae Co. stock logo
NVTA
Invitae
1,700267.01 million284.37 millionOptionable

DGX, LH, GH, NVTA, and EKTAY Headlines

SourceHeadline
Labcorp to acquire Invitae assets for $239 millionLabcorp to acquire Invitae assets for $239 million
uk.investing.com - April 26 at 8:57 AM
Labcorp wins $239M bid for bankrupt InvitaeLabcorp wins $239M bid for bankrupt Invitae
bizjournals.com - April 26 at 8:57 AM
Labcorps Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae DealLabcorp's Q1 Revenue Surpasses Forecasts; Analysts Scrutinize Invitae Deal
msn.com - April 25 at 5:56 PM
Invitae Corporation: Invitae Enters into Agreement with Labcorp for Sale of BusinessInvitae Corporation: Invitae Enters into Agreement with Labcorp for Sale of Business
finanznachrichten.de - April 25 at 12:55 PM
Labcorp Acquiring Invitae Assets for $239M, Posts 5 Percent Rise in Q1 RevenuesLabcorp Acquiring Invitae Assets for $239M, Posts 5 Percent Rise in Q1 Revenues
360dx.com - April 25 at 12:55 PM
Labcorp to Buy Assets of Bankrupt Invitae for $239MLabcorp to Buy Assets of Bankrupt Invitae for $239M
marketwatch.com - April 25 at 7:55 AM
Clinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mlnClinical lab operator Labcorp to buy bankrupt genetic test maker Invitae for $239 mln
reuters.com - April 24 at 10:25 PM
Invitae Enters into Agreement with Labcorp for Sale of BusinessInvitae Enters into Agreement with Labcorp for Sale of Business
finance.yahoo.com - April 24 at 9:54 PM
Labcorp Announces Winning Bid for Select Assets of InvitaeLabcorp Announces Winning Bid for Select Assets of Invitae
prnewswire.com - April 24 at 9:27 PM
Invitae (NYSE:NVTA) Receives New Coverage from Analysts at StockNews.comInvitae (NYSE:NVTA) Receives New Coverage from Analysts at StockNews.com
americanbankingnews.com - April 23 at 2:14 AM
Invitae Publishes its Environmental, Social and Governance (ESG) ReportInvitae Publishes its Environmental, Social and Governance (ESG) Report
tmcnet.com - April 22 at 6:26 PM
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain SignificanceInvitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
finance.yahoo.com - April 11 at 1:32 PM
Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain SignificanceInvitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance
prnewswire.com - April 11 at 11:30 AM
Pioneering cancer test company wants court to slow potential sale of Invitaes cancer-monitoring productsPioneering cancer test company wants court to slow potential sale of Invitae's cancer-monitoring products
bizjournals.com - April 2 at 8:52 PM
Invitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant ClassificationInvitae Launches Update to Invitae Generation™: Clinical Variant Modeling Improves Variant Classification
finance.yahoo.com - March 12 at 9:55 AM
NVTA.PKNVTA.PK
reuters.com - March 11 at 7:21 PM
NVTA.NNVTA.N
reuters.com - March 9 at 7:13 PM
Invitae Corporation: Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial ResultsInvitae Corporation: Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
finanznachrichten.de - March 6 at 5:56 PM
Invitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial ResultsInvitae Reports Estimated Unaudited Fourth Quarter and Full Year 2023 Financial Results
prnewswire.com - March 6 at 7:15 AM
Invitae to Present Data at the 2024 ACMG Annual Clinical Genetics MeetingInvitae to Present Data at the 2024 ACMG Annual Clinical Genetics Meeting
prnewswire.com - March 5 at 7:30 AM
NVTA Jun 2024 0.500 putNVTA Jun 2024 0.500 put
finance.yahoo.com - March 3 at 11:03 PM
NVTA Jan 2026 1.500 callNVTA Jan 2026 1.500 call
finance.yahoo.com - February 26 at 12:20 AM
NVTA Mar 2024 0.500 putNVTA Mar 2024 0.500 put
finance.yahoo.com - February 17 at 12:16 AM
San Franciscos Invitae Seeks Lifeline in Bankruptcy Filing Amid $1.6 Billion DebtSan Francisco's Invitae Seeks Lifeline in Bankruptcy Filing Amid $1.6 Billion Debt
hoodline.com - February 15 at 5:26 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Quest Diagnostics logo

Quest Diagnostics

NYSE:DGX
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Elekta AB (publ) logo

Elekta AB (publ)

OTCMKTS:EKTAY
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services. It also provides Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; Geneva, an applicator for cervical cancer treatment; veterinary radiation therapy products; and Elekta Kaiku for personalized cancer care. In addition, the company offers stereotactic radiosurgery, such as Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Elekta Esprit. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System for minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
Guardant Health logo

Guardant Health

NASDAQ:GH
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Laboratory Co. of America logo

Laboratory Co. of America

NYSE:LH
Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs), including health fairs, on-site and at-home testing, vaccinations, and health screenings. In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; and drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.
Invitae logo

Invitae

NYSE:NVTA
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.